Close Menu

expressed RNAi

The company also announced deals for new DNA production and delivery technologies.

NEW YORK (GenomeWeb) – Benitec Biopharma this week announced that it has licensed its expressed RNAi technology to Circuit Therapeutics for the development of an intractable pain treatment.

NEW YORK (GenomeWeb) – Benitec Biopharma said this week that laboratory data on the first patient dosed in its Phase I/IIa trial its expressed RNAi treatment for hepatitis C indicate that the drug is safe and well tolerated.

NEW YORK (GenomeWeb) – Benitec Biopharma this week announced that it is appealing the European Patent Office's recent revocation of a patent covering the company's core expressed RNAi technology, which had been successfully challenged by biotech firm Galapagos and agro-chemical giant BASF.

NEW YORK (GenomeWeb) – Benitec Biopharma last week disclosed delays in its efforts to dose patients in a Phase I/IIa trial of its expressed RNAi-based hepatitis C treatment TT-034 and said that it is taking steps to speed subject enrollment.

NEW YORK (GenomeWeb) – CalImmune this week announced that it has been cleared by the US Food and Drug Administration to treat a second cohort of patients in a clinical trial of its expressed RNAi-based treatment for HIV infection.

NEW YORK (GenomeWeb) – Just months after disclosing that it is reestablishing its American footprint with a laboratory in Northern California, Australia's Benitec Biopharma announced that it has formally arranged for its stock to be traded in the US on the over-the-counter (OTC) market.

NEW YORK (GenomeWeb) – Benitec Biopharma last week announced that the European Patent Office has upheld its previous decision to revoke one of the company's core patents based on opposition filed by biotech firm Galapagos and chemical giant BASF.

With an investigational new drug application ready for submission to US regulators, Australian firm Benitec Biopharma anticipates launching a phase I/IIa study of its hepatitis C treatment TT-034 before the end of the year, the company's chief executive said this week.

Australian expressed RNAi firm Benitec Biopharma provided an update on its research and development activities late last month, reporting that it remains on track to move its lead drug candidate, the hepatitis C therapy TT-034, into the clinic as early as this month.

Pages

New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.

A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.

Broad Institute researchers describe an approach they've dubbed "DNA microscopy."

In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.